ocal and systemic markers of inflammation and circadian rhythmicity in COVID-19 disease and their role in the prediction of clinical outcome

• Conditions: J80; F05; Adult respiratory distress syndrome; Viral agents as the cause of diseases classified to other chapters; Delirium, not induced by alcohol and other psychoactive substances; Acute renal failure; B97; N17

• Registration Number: DRKS00021522
• Lead Sponsor: niversitätsklinik Freiburg, Klinik für Anästhesiologie und Intensivmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-22
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

1. Adults (> 18 years) male or female patient;
2. Detection of SARS-CoV2 in the nose or throat swab or in the bronchoalveolar lavage;
3. Need for intensive care therapy in the intensive care unit;
4. Ability to consent, either personally or through an authorized person/proxy

Exclusion Criteria

1. children <18 years;
2. Patients with congenital immune defects;
3. Patients with pre-existing cognitive impairment

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Contingency table: mRS categories vs. inflammation high / inflammation low categories

Secondary Outcome Measures

Name	Time	Method
Inflammation high/ low categories vs. rate of delirium, expression of circadian genes, duration of sedation and ventilation, rate of kidney failure, rate of thrombembolic events, ICU length of stay, survival, quality of life after 6 months.